Full-Time
Cultivation Agent
Updated on 9/3/2026
Cresco Labs
1,001-5,000 employees
Cannabis cultivation, processing, and retailing
Compensation Overview
$18/hr
No H1B Sponsorship
Kankakee, IL, USA
In Person
 Manufacturing & Production Operations |
|---|
Get referred to Cresco Labs
See people who can refer or advise you
- Two years of experience in general production, preferably in a regulated field producing for human consumption, or a satisfactory combination of experience and training demonstrating the ability to perform the duties.
- Effective time-management skills and the ability to multitask.
- Ability to perform job duties in indoor and greenhouse climates with varying weather conditions.
- Ability to work in a fast-paced, changing, and challenging environment.
- Ability to work around plant material, including possible exposure to plant pollen and dust.
- Ability to sit, stand, kneel, and perform repetitive hand actions for long periods.
- Ability to lift up to 50 pounds to torso level.
- Must be at least 21 years of age.
- Must comply with legal and company regulations for working in the cannabis industry.
- Must be legally authorized to work permanently in the United States without current or future sponsorship.
- Ensure plant health by pruning, topping, and trimming plants according to company policy and completing other required tasks.
- Move plants efficiently and orderly between areas of the cultivation facility.
- Move Rockwool for plant transplanting.
- Transplant smaller plants into larger pots.
- Perform assigned duties to maintain a clean and safe cultivation facility, including safely disposing of waste.
- Maintain the cleanliness of cultivation equipment and tools, including light reflectors, containers, mixing tools, application tools, and ventilation equipment.
- Assist the Cultivation Manager with tracking plants from birth to harvest through accurate documentation of applicable activities.
- Maintain accurate documentation of plant tracking numbers, lot numbers, and other applicable information.
- Experience in a regulated field producing products for human consumption.
Cresco Labs grows, processes, and retails cannabis products in eleven states, serving adult-use and medical markets. Its products come from its own cultivation and manufacturing facilities and are sold under a portfolio of trusted brands to ensure consistency. It differentiates itself through vertical integration—grower, processor, retailer—operating in high-demand, well-regulated markets to maintain quality and supply. Its goal is to expand market presence while upholding responsible practices, collaborating with governments, using eco-friendly packaging, and delivering value to shareholders and communities.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Chicago, Illinois
Founded
2013
Get referred to Cresco Labs
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue hit $173.3 million, up 15% sequentially and net income $15.4 million.
- Q2 adjusted EBITDA reached $39.5 million, while free cash flow turned positive at $6.5 million.
- September 2 PharmaCann deal added nine stores for $50 million, immediately accretive.
What critics are saying
- Palomar sued on August 14, 2026, denying defense coverage for Cresco's cannabis marketing class actions.
- Two May 4 class actions accuse Cresco of deceptive health claims and seek economic damages.
- CFO Sharon Schuler stepped down August 2026, and replacement risk shadows Pennsylvania integration.
What makes Cresco Labs unique
- Cresco's Pennsylvania integration makes it state's top medical retailer and wholesaler.
- Sunnyside retail plus branded wholesale gives Cresco direct consumer and shelf access.
- Needham Bank's 7.99% revolver gives Cresco conventional banking access uncommon for cannabis operators.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Paid Vacation
Paid Holidays
401(k) Company Match
401(k) Retirement Plan
Performance Bonus
Stock Options
Employee Discounts
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%420 with CNW - convenience is giving an edge to entities selling marijuana. September 4, 2026 Marijuana companies are increasingly betting that convenience will determine what consumers buy, as shoppers show growing interest in products that require little preparation and can fit easily into everyday routines. The shift is particularly visible among newer cannabis customers, who may be less comfortable with traditional consumption methods. An analysis of Headset data found that disposable, all-in-one vaporizers generated roughly $2.82 billion from 94.8 million units, representing annual gains of 23.8% in sales and 22.9% in volume. The average price was about $29.77. Meanwhile, cartridges, historically the biggest vape category, recorded approximately $2.89 billion in sales but declined 14.1% in sales and 8% in unit volume. Their average price was lower, at $19.66, suggesting cost alone does not explain the difference. For many buyers, simplicity appears to be more important. A similar development is occurring in pre-rolls. Infused versions reached about $1.8 billion and posted increases of 13.4% in sales and 21% in volume. Multi-unit packages are also expanding, giving brands such as Dogwalkers additional room to grow. The appeal extends beyond smoking products. Cresco Labs is preparing to introduce High Supply SLIPS, an oral marijuana pouch, through its Sunnyside stores. The product is expected to come in two flavors and offer 4-milligram and 10-milligram doses. The concept draws from the growing popularity of nicotine pouches. Philip Morris reported shipping nearly 165 million cans of Zyn during the fourth quarter of 2025, a 42% increase from a year earlier. Dana Mason, a Cresco brand manager, said demand for simpler inhalable products helped signal an opportunity for consumption methods that do not require smoking. Oral pouches could appeal to consumers at sporting venues, restaurants, and on public transportation, where lighting a joint or using a vape may not be practical. The convenience trend is also influencing hemp-derived products. According to Edibles.com president Thomas Winstanley, some consumers are incorporating THC gummies and chews into routines that resemble supplement use, while others view hemp beverages as an alternative to alcohol. Wider retail availability may further encourage experimentation. Products appearing in familiar outlets such as Total Wine and Circle K can give curious customers an alternative to visiting a dispensary. Experts expect the next stage of innovation to emphasize discretion, including tinctures, sublingual products, and other low-effort formats. As cannabis companies compete for new customers, reducing the number of steps between purchase and consumption could become an increasingly important advantage. The extent to which marijuana firms like Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF) leverage this emerging trend could determine the magnitude of their sales growth over the coming years as more first-time customers shop for cannabis products. About CNW420 CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern - a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis. To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only) Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer CannabisNewsWire is powered by IBN Select A Month
Marijuana MSO Cresco scoops up PharmaCann Pennsylvania assets. September 3, 2026 Cannabis Industry News Key points. * Cresco acquires PharmaCann Pennsylvania assets to expand regional footprint * Transaction positions Cresco as the top MMJ retailer and wholesaler in Pennsylvania * Deal highlights ongoing consolidation trends among major multi-state operators Multi-state operator Cresco Labs has acquired key Pennsylvania assets from rival PharmaCann, significantly expanding its footprint in the second-largest medical marijuana market in the United States. This strategic transaction establishes Cresco as the top medical cannabis retailer and wholesaler in Pennsylvania. The deal brings additional operational facilities and retail storefronts into Cresco's existing portfolio, consolidating market share in a limited-license state where vertical integration drives profitability. As consolidation accelerates across regulated state markets, large operators continue utilizing M&A strategies to capture supply chain dominance and secure consumer touchpoints. For dispensary owners and brand managers operating in the region, this shift signals a changing competitive dynamic - one where scaled operators hold distinct advantages in wholesale pricing and distribution reach. Compliance overhead and supply chain logistics will likely remain central focus areas as integration proceeds. What this means for your brand. Dispensaries and brands in Pennsylvania must prepare for increased market consolidation and stronger wholesale competition. Regional brands should focus on differentiation and strong retail partnerships to maintain shelf space against expanding MSOs.
Cresco Labs acquires nine Pennsylvania dispensaries for $50M. September 2, 2026 Cresco Labs has completed the $50 million acquisition of nine operating medical marijuana dispensaries in Pennsylvania from PharmaCann Penn, expanding its retail footprint and strengthening its position in one of the company's core markets. The transaction gives Cresco 100% of the outstanding equity interests in PharmaCann Penn and makes the company Pennsylvania's largest medical marijuana retailer, according to Cresco. The acquisition complements its existing position as the state's largest wholesaler, increasing the scale of a vertically integrated operation spanning cultivation, branded products, distribution and retail. Pennsylvania generated more than $1.1 billion in medical marijuana sales last year, making it the second-largest medical marijuana market, according to the company. The size of the market and Cresco's existing infrastructure were central to the rationale for deploying additional capital in the state. The $50 million purchase price was funded through a combination of cash and a seller note. The transaction was completed on a cash-free, debt-free basis with an agreed normalized level of working capital. Cresco expects the acquisition to be immediately accretive to revenue, margins and cash flow. Adding nine operating stores also provides a faster path to expanding distribution than developing new retail locations individually, while allowing the company to leverage cultivation and wholesale infrastructure already in place. "We are focused on deploying capital into opportunities that strengthen our competitive position and generate attractive long-term returns," CEO Charlie Bachtell said. He described Pennsylvania as a core market where greater scale and vertical integration can provide competitive advantages. The transaction is particularly significant because it increases Cresco's ability to distribute products through both wholesale and company-operated retail channels. Its portfolio includes Cresco, High Supply, FloraCal, Good News, Wonder Wellness Co., Mindy's and Remedi, while the company operates dispensaries nationally under the Sunnyside brand. Expanding the number of retail locations creates additional outlets for that product portfolio while increasing Cresco's direct exposure to Pennsylvania patients. At the same time, its wholesale operation continues to provide distribution through the broader market, giving the company multiple channels through which to use its cultivation and production capacity. That combination is central to Cresco's Pennsylvania strategy. Rather than entering a new geography that would require significant new infrastructure, the company is deploying $50 million into a market where it already has operating scale. The acquired dispensaries can therefore be paired with existing cultivation, production and wholesale capabilities, creating opportunities to spread infrastructure costs across a larger revenue base. Bachtell said pairing additional retail locations with Cresco's cultivation and wholesale operations reinforces the company's market position and its strategy of pursuing consolidation in markets where it already has meaningful scale. The acquisition also reflects a selective approach to cannabis industry consolidation, with Cresco emphasizing transactions expected to contribute immediately to financial performance. The company has identified revenue, margin and cash-flow accretion from the Pennsylvania deal rather than relying primarily on longer-term market expansion to support the investment rationale. For Cresco, the nine-store portfolio adds operating assets in a medical marijuana market that already exceeds $1 billion in annual sales. The combination of a larger retail network and its existing wholesale leadership gives the company greater reach across the state while creating another avenue for deploying its branded product portfolio. With the PharmaCann Penn transaction closed, Cresco has increased its exposure to a market it considers strategically important while using existing infrastructure to support the acquired operations. The company's ability to generate incremental sales and cash flow from those stores will be a key measure of the acquisition as it integrates the additional retail footprint into its Pennsylvania platform.
Cresco Labs acquires nine Pennsylvania dispensaries in accretive Transaction to strengthen market leadership. Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) ("Cresco Labs" or the "Company") today announced the closing of its acquisition of 100% of the outstanding equity interests in PharmaCann Penn, LLC ("PharmaCann") for an aggregate consideration of US$50 million (the "Transaction"). The Transaction consists of nine operational retail medical marijuana dispensaries in Pennsylvania, advancing...
Psychedelic medicine gets federal attention, CBD program update. In its latest Trade To Black, presented by Flowhub, hosts Shadd Dales and Anthony Varrell break down a new federal report that could reshape how states handle psychedelic medicine going forward - plus the weekly NuggMD safety poll and an update on the CBD pilot program with Dr. Paul Shields. In the headlines, The Dales Report track another grind higher for the sector. MSOS pushed above the $5 mark before pulling back to close near $4.85 on roughly five million shares. Trulieve continued to outpace peers like GTI, Verano and Cresco, finishing around $11.43 after touching $11.85 intraday - a move The Dales Report tie to its recent uplisting, which opened the name to buyers who can't access OTC markets. The Dales Report also flag tomorrow's pre-recorded interview with Adam Stettner of FundCanna. For the Check-In Poll of the Week, presented by NuggMD, 513 respondents were asked what one thing they'd fix about cannabis safety if they could. Stronger testing standards led at 40%, followed by clearer education on products and dosing at 26%, easier and more affordable access to licensed markets at 21%, and cracking down on unregulated products at 13%. The Dales Report connect the results to the ongoing trust gap around untested THCA flower sold outside the licensed framework. From there, Matthew "Whiz" Buckley - founder of Top Gun Options, former fighter pilot, and a longtime voice in psychedelic investing - joins to unpack a new SAMHSA report urging states to plan now, before formal FDA approval of substances like psilocybin and MDMA. The guidance flags Medicaid coverage questions, oversight frameworks, and the legal tension between state and federal law as issues to address before approval, not after. The Dales Report dig into the FDA's unusually fast rolling reviews for companies like Compass Pathways and Definium Therapeutics, and why a Big Pharma buyout looms over the space. Closing out the show is the weekly Vantage Standard segment, presented by Vantage Hemp. Dr. Paul Shields, Chief Medical Officer at Vantage Hemp, returns with an update on the CBD pilot program. Announced in March and live by April, it drew five ACOs but little traction, and Shields explains why he expects no further movement this year. He points instead to the 10-year LEAD program beginning January 1, 2027, and argues that cannabis rescheduling - not this pilot - is the real catalyst for cannabinoid therapy. This and more when you tune in.